Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Frontiers in OncologyOpen Access

Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEunju ShinSKSeung Il KimMPMin-ho Park

Discussion

Loading...

Member takes

Overview

Comparative analysis indicates ovarian function suppression may worsen bone mineral density in premenopausal patients with breast cancer.

Key Points

  • Ovarian function suppression led to a greater incidence of bone mineral density loss in patients at baseline, and there was a significant risk of deterioration.
  • The study included 522 premenopausal women, with a median age of 41.1 years, and evaluated bone mineral density changes over 5 years post-diagnosis.
  • Using dual-energy X-ray absorptiometry, bone density was measured at baseline and reevaluated 3 and 5 years after for changes across categories.
  • This study highlights the potential need for monitoring bone health in patients receiving ovarian function suppression for estrogen receptor-positive breast cancer.

Cite This Study

Shin et al. (2025) studied this question.

synapsesocial.com/papers/68e034f7f0e39f13e7fa31cdhttps://doi.org/10.3389/fonc.2025.1465256
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of different endocrine therapies on bone mineral density and fracture risk in postmenopausal breast cancer patients: a meta-analysis2025 · 1 citations
  2. 2Impact of ovarian function suppression on prognosis in premenopausal patients with HR+/HER2 + early-stage breast cancer: a multi-center retrospective study2025
  3. 3Self-Reported Outcomes of Endocrine Therapy with or Without Ovarian Suppression in Premenopausal Breast Cancer Patients: A Brazilian Quality-of-Life Prospective Cohort2025
  4. 4Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy2025
  5. 5Behavior of Osteoblastic Lineage Cells When in the Presence of Tamoxifen: In Vitro and In Vivo Studies on Osseointegration2025